Curiously, as a result of Galunisertib treatment, a reduced serum levels of MPO, IL-1β and IL-6 were observed in the acute pancreatitis model, implying those factors could also contribute to mesenchymal activation.30 The gene discussed is MPO; the disease is acute pancreatitis.